|
|
Vaccine Detail
|
Dendritic Cell/Myeloma Fusion Vaccine |
| Vaccine Information |
- Vaccine Name: Dendritic Cell/Myeloma Fusion Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: whole cell cancer vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: tumor associated antigens (TAAs) (NCIT_C158480)
- Immunization Route: subcutaneous injection
- Description: This is a therapeutic cancer vaccine consisting of autologous dendritic cells (DCs) fused with patient-derived plasma cell (multiple) myeloma cells with potential immunostimulatory and antineoplastic activities. Autologous DC/multiple myeloma fusions stimulate both helper and cytotoxic T-lymphocyte (CTL) responses through the presentation of internalized and newly synthesized tumor associated antigens (TAAs). This may promote cellular and humoral antitumor immune responses in patients with plasma cell myeloma. (NCIT_C158480) This vaccine uses Dendritic cell/myeloma fusions with granulocyte macrophage colony-stimulating factor (GM-CSF) adjuvant plus lenalidomide maintenance therapy. The dendritic cell myeloma vaccine may improve response in patients with multiple myeloma after autologous Hematopoietic Cell Transplant (HCT). (NCT02728102)
|
| Host Response |
|
|
| References |
NCIT_C158480: Autologous Dendritic Cell/Myeloma Fusion Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C158480]
NCT02728102: Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401) [https://clinicaltrials.gov/study/NCT02728102]
|
|
